Agilent Technologies, Inc. (0HAV.L)
USD 102.88
(0.03%)
USD 102.88
(0.03%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.11 Billion USD | 0.52% |
| 2022 | 2.1 Billion USD | 2.14% |
| 2021 | 2.06 Billion USD | 3.47% |
| 2020 | 1.99 Billion USD | 6.81% |
| 2019 | 1.86 Billion USD | 5.97% |
| 2018 | 1.75 Billion USD | 12.18% |
| 2017 | 1.56 Billion USD | -0.88% |
| 2016 | 1.58 Billion USD | 4.15% |
| 2015 | 1.51 Billion USD | -45.0% |
| 2014 | 2.76 Billion USD | 6.89% |
| 2013 | 2.58 Billion USD | 3.98% |
| 2012 | 2.48 Billion USD | 1.1% |
| 2011 | 2.45 Billion USD | 3.98% |
| 2010 | 2.36 Billion USD | 5.3% |
| 2009 | 2.24 Billion USD | -6.5% |
| 2008 | 2.4 Billion USD | 0.67% |
| 2007 | 2.38 Billion USD | 8.71% |
| 2006 | 2.19 Billion USD | -6.28% |
| 2005 | 2.34 Billion USD | -14.47% |
| 2004 | 2.73 Billion USD | -9.34% |
| 2003 | 3.01 Billion USD | -23.04% |
| 2002 | 3.92 Billion USD | -2.12% |
| 2001 | 4 Billion USD | -4.53% |
| 2000 | 4.19 Billion USD | 31.11% |
| 1999 | 3.2 Billion USD | -7.86% |
| 1998 | 3.47 Billion USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 493 Million USD | -3.9% |
| 2024 Q3 | 522 Million USD | 5.88% |
| 2024 Q1 | 513 Million USD | 1.18% |
| 2023 FY | 2.11 Billion USD | 0.52% |
| 2023 Q3 | 525 Million USD | -2.96% |
| 2023 Q1 | 542 Million USD | 0.18% |
| 2023 Q2 | 541 Million USD | -0.18% |
| 2023 Q4 | 507 Million USD | -3.43% |
| 2022 Q1 | 534 Million USD | 5.74% |
| 2022 Q3 | 528 Million USD | 5.39% |
| 2022 FY | 2.1 Billion USD | 2.14% |
| 2022 Q4 | 541 Million USD | 2.46% |
| 2022 Q2 | 501 Million USD | -6.18% |
| 2021 Q4 | 505 Million USD | -2.13% |
| 2021 Q1 | 510 Million USD | 4.29% |
| 2021 Q2 | 529 Million USD | 3.73% |
| 2021 Q3 | 516 Million USD | -2.46% |
| 2021 FY | 2.06 Billion USD | 3.47% |
| 2020 Q2 | 555 Million USD | 9.25% |
| 2020 Q4 | 489 Million USD | 11.39% |
| 2020 FY | 1.99 Billion USD | 6.81% |
| 2020 Q3 | 439 Million USD | -20.9% |
| 2020 Q1 | 508 Million USD | 4.31% |
| 2019 FY | 1.86 Billion USD | 5.97% |
| 2019 Q4 | 487 Million USD | 4.28% |
| 2019 Q3 | 467 Million USD | 3.09% |
| 2019 Q2 | 453 Million USD | -0.88% |
| 2019 Q1 | 457 Million USD | -0.65% |
| 2018 Q4 | 460 Million USD | 5.5% |
| 2018 Q1 | 434 Million USD | 4.83% |
| 2018 Q3 | 436 Million USD | 1.63% |
| 2018 Q2 | 429 Million USD | -1.15% |
| 2018 FY | 1.75 Billion USD | 12.18% |
| 2017 Q1 | 368 Million USD | -9.14% |
| 2017 Q4 | 414 Million USD | 4.81% |
| 2017 Q3 | 395 Million USD | 1.02% |
| 2017 FY | 1.56 Billion USD | -0.88% |
| 2017 Q2 | 391 Million USD | 6.25% |
| 2016 FY | 1.58 Billion USD | 4.15% |
| 2016 Q4 | 405 Million USD | 2.27% |
| 2016 Q2 | 399 Million USD | 4.45% |
| 2016 Q1 | 382 Million USD | 0.79% |
| 2016 Q3 | 396 Million USD | -0.75% |
| 2015 Q4 | 379 Million USD | 2.71% |
| 2015 Q2 | 373 Million USD | -6.28% |
| 2015 Q1 | 398 Million USD | -44.95% |
| 2015 FY | 1.51 Billion USD | -45.0% |
| 2015 Q3 | 369 Million USD | -1.07% |
| 2014 FY | 2.76 Billion USD | 6.89% |
| 2014 Q3 | 685 Million USD | -0.58% |
| 2014 Q4 | 723 Million USD | 5.55% |
| 2014 Q1 | 665 Million USD | 6.74% |
| 2014 Q2 | 689 Million USD | 3.61% |
| 2013 FY | 2.58 Billion USD | 3.98% |
| 2013 Q2 | 678 Million USD | 2.26% |
| 2013 Q3 | 620 Million USD | -8.55% |
| 2013 Q4 | 623 Million USD | 0.48% |
| 2013 Q1 | 663 Million USD | 2.95% |
| 2012 FY | 2.48 Billion USD | 1.1% |
| 2012 Q4 | 644 Million USD | 3.87% |
| 2012 Q3 | 620 Million USD | 0.32% |
| 2012 Q2 | 618 Million USD | 2.49% |
| 2012 Q1 | 603 Million USD | -0.82% |
| 2011 FY | 2.45 Billion USD | 3.98% |
| 2011 Q3 | 611 Million USD | -3.63% |
| 2011 Q1 | 605 Million USD | -4.12% |
| 2011 Q2 | 634 Million USD | 4.79% |
| 2011 Q4 | 608 Million USD | -0.49% |
| 2010 Q4 | 631 Million USD | 3.44% |
| 2010 Q3 | 610 Million USD | 9.52% |
| 2010 Q2 | 557 Million USD | -1.59% |
| 2010 FY | 2.36 Billion USD | 5.3% |
| 2010 Q1 | 566 Million USD | 0.53% |
| 2009 Q4 | 563 Million USD | 4.26% |
| 2009 FY | 2.24 Billion USD | -6.5% |
| 2009 Q1 | 565 Million USD | -2.25% |
| 2009 Q2 | 577 Million USD | 2.12% |
| 2009 Q3 | 540 Million USD | -6.41% |
| 2008 FY | 2.4 Billion USD | 0.67% |
| 2008 Q1 | 622 Million USD | 3.67% |
| 2008 Q3 | 585 Million USD | -5.03% |
| 2008 Q2 | 616 Million USD | -0.96% |
| 2008 Q4 | 578 Million USD | -1.2% |
| 2007 Q2 | 599 Million USD | 0.5% |
| 2007 Q4 | 600 Million USD | 1.69% |
| 2007 Q3 | 590 Million USD | -1.5% |
| 2007 Q1 | 596 Million USD | 67.42% |
| 2007 FY | 2.38 Billion USD | 8.71% |
| 2006 Q2 | 620 Million USD | -2.21% |
| 2006 Q3 | 584 Million USD | -5.81% |
| 2006 Q4 | 356 Million USD | -39.04% |
| 2006 FY | 2.19 Billion USD | -6.28% |
| 2006 Q1 | 634 Million USD | 110.63% |
| 2005 Q3 | 676 Million USD | -4.52% |
| 2005 Q4 | 301 Million USD | -55.47% |
| 2005 FY | 2.34 Billion USD | -14.47% |
| 2005 Q1 | 656 Million USD | -5.07% |
| 2005 Q2 | 708 Million USD | 7.93% |
| 2004 Q4 | 691 Million USD | 0.29% |
| 2004 Q3 | 689 Million USD | -1.15% |
| 2004 Q1 | 660 Million USD | 0.76% |
| 2004 FY | 2.73 Billion USD | -9.34% |
| 2004 Q2 | 697 Million USD | 5.61% |
| 2003 Q1 | 785 Million USD | -22.05% |
| 2003 FY | 3.01 Billion USD | -23.04% |
| 2003 Q4 | 655 Million USD | -11.25% |
| 2003 Q3 | 738 Million USD | -12.25% |
| 2003 Q2 | 841 Million USD | 7.13% |
| 2002 FY | 3.92 Billion USD | -2.12% |
| 2002 Q4 | 1 Billion USD | 3.39% |
| 2002 Q3 | 974 Million USD | 2.31% |
| 2002 Q2 | 952 Million USD | -3.84% |
| 2002 Q1 | 990 Million USD | 0.92% |
| 2001 Q1 | 1.11 Billion USD | -5.84% |
| 2001 Q4 | 981 Million USD | -2.1% |
| 2001 Q3 | 1 Billion USD | -3.47% |
| 2001 Q2 | 1.03 Billion USD | -6.74% |
| 2001 FY | 4 Billion USD | -4.53% |
| 2000 Q3 | 1.09 Billion USD | 8.02% |
| 2000 Q1 | 915 Million USD | 112.06% |
| 2000 FY | 4.19 Billion USD | 31.11% |
| 2000 Q2 | 1.01 Billion USD | 10.38% |
| 2000 Q4 | 1.18 Billion USD | 8.34% |
| 1999 Q4 | -7.59 Billion USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | 3.2 Billion USD | -7.86% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 FY | 3.47 Billion USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | -641.881% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -4260.645% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -17320.311% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -417.36% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -17.496% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -394.562% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -3693.314% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -667.158% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -343.992% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -21.115% |
| bluebird bio, Inc. | 240.23 Million USD | -780.399% |
| Blueprint Medicines Corporation | 722.86 Million USD | -192.587% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1384.596% |
| Imunon, Inc. | 21.03 Million USD | -9956.856% |
| Adicet Bio, Inc. | 152.03 Million USD | -1291.1% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -473.774% |
| Dynavax Technologies Corporation | 219.14 Million USD | -865.114% |
| Editas Medicine, Inc. | 247.3 Million USD | -755.223% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -102.586% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -677.868% |
| Exelixis, Inc. | 1.58 Billion USD | -33.289% |
| FibroGen, Inc. | 398.11 Million USD | -431.256% |
| Geron Corporation | 70.44 Million USD | -2902.513% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -606.606% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -1652.903% |
| Illumina, Inc. | 3.81 Billion USD | 44.532% |
| Incyte Corporation | 1.19 Billion USD | -77.657% |
| Insmed Incorporated | 949.26 Million USD | -122.805% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -283.454% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -171.297% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -368.965% |
| IQVIA Holdings Inc. | 2.05 Billion USD | -3.02% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -5301.885% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -94.145% |
| Evolus, Inc. | 189.75 Million USD | -1014.572% |
| Myriad Genetics, Inc. | 600.1 Million USD | -252.441% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -32.477% |
| OPKO Health, Inc. | 574.68 Million USD | -268.027% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -55.421% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -299.803% |
| Verastem, Inc. | 92.08 Million USD | -2196.816% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 94.791% |
| Waters Corporation | 943.51 Million USD | -124.161% |
| Zoetis Inc. | 2.76 Billion USD | 23.508% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 55.707% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 79.374% |
| Biogen Inc. | 5.2 Billion USD | 59.365% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -824.873% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 24.875% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -15105.281% |
| Homology Medicines, Inc. | 9.87 Million USD | -21317.722% |
| Nektar Therapeutics | 190.9 Million USD | -1007.892% |
| TG Therapeutics, Inc. | 198.47 Million USD | -965.625% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1997.652% |
| Perrigo Company plc | 1.52 Billion USD | -38.371% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -4635.039% |